FDA-approved

Skin & aging

Afamelanotide

Evidence

FDA approved

Class

Melanocortin 1 receptor agonist

/

Afamelanotide

KEY TAKEAWAY

Afamelanotide is a melanocortin peptide implant approved to help adults with erythropoietic protoporphyria tolerate sunlight. It increases melanin and reduces pain from light exposure.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A synthetic copy of alpha-MSH delivered as an implant

Approved for

Light-triggered pain in erythropoietic protoporphyria

Key fact

Increased pain-free time in sunlight in a randomized trial

Route

Implant under the skin

Evidence strength

FDA approved

What it is

What it is

Afamelanotide, sold as Scenesse, is a synthetic analog of alpha-melanocyte-stimulating hormone. It comes as a small implant placed under the skin about every two months.

How it works

How it works

It activates the melanocortin 1 receptor on pigment cells, increasing skin melanin and helping protect from light-driven damage.

Regulatory status

Regulatory status

The FDA approved afamelanotide in 2019 for adults with erythropoietic protoporphyria.

What it is used for

What it is used for

Reducing phototoxic reactions in adults with erythropoietic protoporphyria.

Side effects and risks

Side effects and risks

Nausea, headache, implant-site reactions and darkening of skin or moles can occur. Regular skin checks are recommended.

Citations

Citations

Langendonk JG et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373:48-59.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo